<DOC>
<DOCNO>EP-0625351</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Use of Etofibrate and pharmaceutical compositions containing etofibrate in the treatment of diabetic angio- and retinopathy
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3144	A61K920	A61K920	A61K950	A61K3144	A61K950	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K9	A61K9	A61K9	A61K31	A61K9	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The present invention relates to the use of etofibrate for the treatment of diabetic angiopathy and retinopathy and to pharmaceutical compositions which contain etofibrate in the form of pellets and which are particularly suitable for the abovementioned indication.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
MERZ 
&
 CO GMBH 
&
 CO
</APPLICANT-NAME>
<APPLICANT-NAME>
MERZ + CO. GMBH 
&
 CO.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
ERBLER HANS DR MED
</INVENTOR-NAME>
<INVENTOR-NAME>
ERBLER, HANS, DR. MED.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
The use of a pharmaceutical composition containing an effective dose of etofibrate and
customary carrier and additive substances for the production of a drug for the

treatment of diabetic angiopathy, with the exception of necrobiosis lipoidica
diabeticorum.
The use of a composition according to claim 1 for the production of a drug for the
treatment of diabetic retinopathy.
A use according to claims 1 or 2, characterised in that the composition contains an
effective dose of 300 to 1000 mg etofibrate/unit.
A use according to any one of claims 1-3, characterised in that the active ingredient is
used in the form of tablets or capsules.
A use according to any one of claims 1-4, characterised in that gelatine, sorbitol,
polyvinylpyrrolidone or cellulose derivatives are used as the carrier, and fillers,

internal lubricants, disintegration agents and wetting agents are used as the additives.
A use according to any one of claims 1-3, characterised in that the active ingredient is
used in liquid form as an emulsion, as a suspension or as liposomal preparations in

soft gelatine capsules.
</CLAIMS>
</TEXT>
</DOC>
